Does Mounjaro Reduce Blood Pressure — and What Should You Actually Expect?

The misconception worth clearing up first: Mounjaro is not a blood pressure drug

A common assumption (particularly among people who've read about tirzepatide's wide-ranging metabolic effects) is that it actively lowers blood pressure through some direct mechanism on the cardiovascular system. The reality is more precise. Tirzepatide works by activating two gut-hormone receptors, GIP and GLP-1, which reduce appetite, slow the movement of food through the stomach, and support blood sugar regulation. Blood pressure is not a primary target of that mechanism.

What clinical trials did observe, fairly consistently, was that participants who lost significant amounts of weight also tended to see a fall in systolic blood pressure. That is not surprising: sustained weight loss is one of the most reliable non-pharmacological routes to lower blood pressure, and Mounjaro produces substantial weight loss in many people. The reduction in blood pressure seen in trials is widely interpreted as following from the weight loss, not from any separate vascular action of the drug itself.

That distinction matters practically. If you are hoping Mounjaro will lower your blood pressure independently of whether you lose weight, the evidence does not support that expectation. If you are asking whether losing weight with tirzepatide might, over time, take some pressure off your cardiovascular system, the trial data suggests it may, for many people. Those are meaningfully different questions, and your prescriber is the right person to work through which one applies to your situation.

What the SURMOUNT trials actually recorded on blood pressure

In SURMOUNT-1 (the pivotal 72-week trial published in the New England Journal of Medicine) participants receiving tirzepatide at the 15mg maintenance dose lost an average of around 20–21% of body weight. Alongside that, the trial recorded average reductions in systolic blood pressure across tirzepatide arms, with the higher-dose groups showing the more pronounced effects. These reductions were statistically meaningful but modest in absolute terms, typically in the range of a few millimetres of mercury on average across the group.

It is worth being careful with group averages. Some participants saw more noticeable changes; others saw little. Blood pressure is sensitive to many variables (sodium intake, stress, sleep, concurrent medicines) and attributing any observed change solely to tirzepatide would oversimplify what is happening in someone's body over more than a year of treatment.

You can read a fuller breakdown of how Mounjaro affects blood pressure across different patient groups, which sets out the SURMOUNT data in more detail. For people who want to understand the specific question of whether tirzepatide can push blood pressure lower than desired, there is also dedicated information on Mounjaro and low blood pressure, which covers that risk separately.

What this means if you have high blood pressure and are considering tirzepatide

Hypertension is one of the weight-related conditions that can lower the BMI threshold for eligibility under Mounjaro's UK licence, so having high blood pressure does not rule you out, and for some people it is part of what makes treatment clinically appropriate. If you are already prescribed antihypertensives, the relevant question is not whether to stop them but how your prescriber monitors you as your weight changes.

If weight loss does reduce your blood pressure over the course of treatment, your antihypertensive dose may need reviewing downward. That is a good problem to have, but it does require regular monitoring, not something to manage by halving tablets off your own bat. The NHS England guidance on weight management injections specifically flags the importance of wraparound clinical care precisely because the metabolic effects of these medicines interact with existing conditions and existing prescriptions.

A question our prescribers hear fairly regularly is whether someone can stop their blood pressure medicine once they start Mounjaro. The honest answer is: possibly, over time, if weight loss is sustained and blood pressure responds, but that decision belongs to the prescriber who has your full medical history, not to a general information page. Monitoring is the key word here.

If you are curious about the broader picture of what Mounjaro does and does not do for cardiovascular markers, the tirzepatide overview covers the wider evidence base, and the Mounjaro page sets out the UK licence in plain terms. For a direct comparison of the blood pressure question from a different angle, this page on whether Mounjaro lowers blood pressure approaches the same evidence with a slightly different framing.

One practical note: if you order by noon on a weekday and your consultation is approved the same day, your treatment arrives the next working day, which means some people fit the whole process around a lunchtime GP appointment rather than waiting weeks for a referral. People managing multiple conditions often have other practical questions too, such as whether you can have a tattoo while taking Mounjaro, and convenience matters when you're managing multiple conditions at once.

If high blood pressure is part of your health picture and you are wondering whether tirzepatide might be appropriate for you, the right first step is a clinical conversation. You can start a free consultation with our prescribers, a named clinician, not a bot, reads your answers the same day and tells you honestly whether treatment is suitable.